Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders

 Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders

Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders

Shots: 

  • ImmuNext to receive $40M upfront, $565M as development & commercialization milestones and royalties on sales of products. Lilly to get an exclusive WW licence to develop & commercialize novel immuno-therapies 
  • Eli Lilly and ImmuNext plan to build a 3yrs. research collaboration supporting the development of preclinical targets for autoimmune diseases by regulating immune cell metabolism
  • Immunomodulators are molecules that promote or suppress immune responses to restore immune homeostasis and cure disease related to autoimmunity, cancer, transplantation rejection, and infectious disease

Click here to read full press release/ article | Ref: Eli lilly | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post